Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene Cream 0.1% vs TAZORAC® in Acne Vulgaris
NCT02886715Phase 3Completed
- Sponsor
- Fougera Pharmaceuticals Inc.
- Start
- Sep 2016
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tazarotene in acne vulgaris (3 arms), sponsored by Fougera Pharmaceuticals Inc. Primary endpoints: Change in Inflammatory Lesion Counts at 12 weeks and Change in Non-inflammatory Lesion Counts at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02886715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886715.